Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
DexCom, Inc., una empresa de dispositivos médicos, se centra en el diseño, desarrollo y comercialización de sistemas de monitorización continua de glucosa (CGM) para el tratamiento de la diabetes y la salud metabólica en los Estados Unidos e internacionalmente.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $5.0B | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B | $1.9B | $1.5B | $1.0B | $718M | $573M | $402M | $259M | $160M | $100M | $76M | $49M | $30M | $10M | $5M | $2M |
| Beneficio bruto | $3.1B | $2.8B | $2.4B | $2.3B | $1.9B | $1.7B | $1.3B | $932M | $664M | $492M | $378M | $278M | $176M | $100M | $47M | $36M | $18M | $4M | ($6M) | ($8M) | ($9M) |
| % de margen bruto | 62.5% | 60.1% | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% | 63.1% | 64.4% | 68.5% | 66.0% | 69.2% | 68.0% | 62.6% | 46.7% | 47.0% | 37.9% | 12.3% | -56.2% | -175.2% | -405.1% |
| Ingresos operativos (EBIT) | $1.1B | $912M | $600M | $598M | $391M | $266M | $300M | $142M | ($186M) | ($42M) | ($64M) | ($57M) | ($22M) | ($29M) | ($56M) | ($45M) | ($45M) | ($46M) | ($53M) | ($47M) | ($49M) |
| % de margen operativo | 22.9% | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | 15.5% | 9.6% | -18.1% | -5.9% | -11.2% | -14.2% | -8.3% | -18.1% | -55.8% | -58.8% | -93.1% | -154.4% | -537.0% | -1008.8% | -2273.0% |
| Ingresos netos | $1.0B | $836M | $576M | $542M | $341M | $217M | $494M | $101M | ($127M) | ($50M) | ($66M) | ($58M) | ($22M) | ($30M) | ($54M) | ($45M) | ($55M) | ($54M) | ($55M) | ($46M) | ($47M) |
| % de margen neto | 20.1% | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | 25.6% | 6.9% | -12.3% | -7.0% | -11.4% | -14.3% | -8.6% | -18.6% | -54.5% | -58.7% | -113.5% | -180.3% | -560.9% | -991.5% | -2147.6% |
| EBITDA | $1.6B | $1.4B | $946M | $917M | $565M | $378M | $377M | $213M | ($75M) | ($20M) | ($49M) | ($46M) | ($13M) | ($22M) | ($49M) | ($41M) | ($51M) | ($43M) | ($50M) | ($43M) | ($47M) |
| Beneficio por acción (EPS) | $2.51 | $2.06 | $1.40 | $1.27 | $0.80 | $0.51 | $1.27 | $0.27 | $-0.36 | $-0.15 | $-0.20 | $-0.18 | $-0.07 | $-0.10 | $-0.20 | $-0.17 | $-0.24 | $-0.30 | $-0.47 | $-0.41 | $-0.43 |
| Acciones en circulación (M) | 392M | 406M | 413M | 426M | 428M | 429M | 390M | 369M | 353M | 345M | 334M | 319M | 301M | 284M | 275M | 262M | 228M | 177M | 118M | 113M | 109M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de DXCM. /companies/us/DXCM
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms